Blog
RSS FeedPosted by Michael Wonder on 22 May 2025
Tagrisso approved (with conditions) in Canada for patients with unresectable, stage III EGFR-mutated non-small cell lung cancer
21 May 2025 - Based on LAURA Phase 3 trial results which showed patients who took Targrisso after CRT had ...
Posted by Michael Wonder on 19 May 2025
Trump wants to ‘equalize’ and lower drug prices. Could Canada be impacted?
17 May 2025 - US President Donald Trump has launched a new effort to lower prescription drug prices for Americans ...
Posted by Michael Wonder on 14 May 2025
Lilly Canada announces availability of Mounjaro KwikPen (tirzepatide) in all doses, advancing care for adults living with type 2 diabetes
13 May 2025 - The multi-dose, single-patient-use, pre-filled pen allows for personalised treatment plans that can cater to individual patient ...
Posted by Michael Wonder on 09 May 2025
Itulatek approved for treatment of children and adolescents in Canada
8 May 2025 - ALK today announced that Health Canada has approved ALK’s regulatory filing for Itulatek (tree pollen sublingual allergy ...
Posted by Michael Wonder on 06 May 2025
Health Canada has granted approval for Tzield, the first and only disease-modifying therapy in auto-immune type 1 diabetes in Canada
5 May 2025 - Tzield is demonstrated to delay by a median of 2 years the onset of Stage 3 type ...
Posted by Michael Wonder on 04 May 2025
Health Canada accepts semaglutide 2.4 mg, a GLP-1 receptor agonist treatment for MASH, as a supplemental new drug submission under the priority review policy
2 May 2025 - Today, Novo Nordisk Canada announced that Health Canada has accepted for review, under the priority review policy, ...
Posted by Michael Wonder on 29 Apr 2025
Health Canada approves Iqirvo as a first-in-class dual-peroxisome proliferator-activated receptor treatment for primary biliary cholangitis
28 April 2025 - Iqirvo (elafibranor) is the first new medicine approved in nearly a decade for the treatment of ...
Posted by Michael Wonder on 28 Apr 2025
New position statement aims to guide the use of AI methods in health technology assessment
25 April 2025 - Canada’s Drug Agency has published a new position statement on the use of artificial intelligence methods ...
Posted by Michael Wonder on 24 Apr 2025
Sarclisa approved in Canada for patients with newly diagnosed multiple myeloma
22 April 2025 - This is the third indication for Sarclisa in Canada for the treatment of multiple myeloma. ...
Posted by Michael Wonder on 23 Apr 2025
Health Canada approves Keytruda plus pemetrexed and platinum chemotherapy as first-line treatment for adult patients with unresectable advanced or metastatic malignant pleural mesothelioma
22 April 2025 - Approval is based on the results from the Phase 3 CCTG IND.227/KEYNOTE-483 trial. ...
Posted by Michael Wonder on 18 Apr 2025
Canada’s Drug Agency announces new 5 year strategic plan
17 April 2025 - Canada’s Drug Agency announces a new 5-year strategic plan, Insight to Impact 2025–2030. ...
Posted by Michael Wonder on 18 Apr 2025
Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit for these patients
17 April 2025 - Approval based on RUBY Part 1 trial, where Jemperli plus chemotherapy demonstrated a statistically significant and ...
Posted by Michael Wonder on 16 Apr 2025
Scilex announces approval of a new drug submission from the Health Canada for Elyxyb’s acute treatment of migraine with or without aura in Canada
15 April 2025 - Elyxyb is a first-line treatment and the only FDA approved, ready to use oral solution for the ...
Posted by Michael Wonder on 15 Apr 2025
Health Canada approves Nduvra (tapinarof 1% cream) for the topical treatment of plaque psoriasis in adults
14 April 2025 - Organon today announced that Health Canada has approved Nduvra (tapinarof cream), 1%, the first in a novel ...
Posted by Michael Wonder on 11 Apr 2025
Health Canada approves Imfinzi (durvalumab) as the first and only immunotherapy regimen for adult patients with limited-stage small cell lung cancer
10 April 2025 - Health Canada has granted a Notice of Compliance for Imfinzi (durvalumab), as monotherapy, for the treatment ...